[Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]
Standard
[Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]. / Kilic, E; Milde-Langosch, Karin; Müller, Volkmar; Wirtz, R; Henningsen, Maike.
In: PATHOLOGE, Vol. 29, No. 2, 2, 2008, p. 347-352.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]
AU - Kilic, E
AU - Milde-Langosch, Karin
AU - Müller, Volkmar
AU - Wirtz, R
AU - Henningsen, Maike
PY - 2008
Y1 - 2008
N2 - AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is a cell surface immunoglobulin expressed in breast cancer (BC) and is assumed to be implicated in tumourigenesis and tumour progression. The importance of the adhesion molecule ALCAM for the response to taxane-free adjuvant chemotherapy was investigated. MATERIALS AND METHODS: Tissue specimens from 162 primary breast cancer patients were analyzed. Immunohistochemical staining (IHC) and Western blots (WB) were performed using monoclonal antibody against ALCAM. Relative protein amounts in WB bands were determined densitometrically. ALCAM mRNA expression was evaluated by microarray analysis (Affymetrix). RESULTS: In the normal breast ALCAM is expressed in luminal and basal epithelial cells. In BC samples, WB analysis showed a significant positive correlation of ALCAM levels with estrogen receptor status (p=0.04). For patients who received a taxane-free chemotherapy, a high ALCAM expression was predictive for a good response to chemotherapy. Median mRNA expression of ALCAM was 4.5-fold higher in patients alive at the time of follow-up compared to those who died of breast cancer. CONCLUSIONS: Higher ALCAM expression showed a positive correlation with estrogen receptor status and is a useful predictive marker for the response to taxane-free chemotherapy.
AB - AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is a cell surface immunoglobulin expressed in breast cancer (BC) and is assumed to be implicated in tumourigenesis and tumour progression. The importance of the adhesion molecule ALCAM for the response to taxane-free adjuvant chemotherapy was investigated. MATERIALS AND METHODS: Tissue specimens from 162 primary breast cancer patients were analyzed. Immunohistochemical staining (IHC) and Western blots (WB) were performed using monoclonal antibody against ALCAM. Relative protein amounts in WB bands were determined densitometrically. ALCAM mRNA expression was evaluated by microarray analysis (Affymetrix). RESULTS: In the normal breast ALCAM is expressed in luminal and basal epithelial cells. In BC samples, WB analysis showed a significant positive correlation of ALCAM levels with estrogen receptor status (p=0.04). For patients who received a taxane-free chemotherapy, a high ALCAM expression was predictive for a good response to chemotherapy. Median mRNA expression of ALCAM was 4.5-fold higher in patients alive at the time of follow-up compared to those who died of breast cancer. CONCLUSIONS: Higher ALCAM expression showed a positive correlation with estrogen receptor status and is a useful predictive marker for the response to taxane-free chemotherapy.
M3 - SCORING: Zeitschriftenaufsatz
VL - 29
SP - 347
EP - 352
JO - PATHOLOGE
JF - PATHOLOGE
SN - 0172-8113
IS - 2
M1 - 2
ER -